TABLE 3.
Failure (n = 110) | No Failure (n = 47) | P | |
---|---|---|---|
Independent variables | |||
Age, y, median (IQR) | 3 (1.8 to 5.0) | 3 (1.2 to 7.0) | .93 |
SES z score, median (IQR)a | −3.5 (−7.0 to −1.6) | −3.0 (−5.8 to −1.0) | .26 |
LOS, d, median (IQR) | 1.9 (1.2 to 3.1) | 2.3 (1.7 to 3.2) | .06 |
Sex of child, female, n (%) | 50 (46) | 26 (55) | .26 |
Race and/or ethnicity, n (%) | .03 | ||
Hispanic | 41 (37) | 16 (34) | |
Non-Hispanic African American | 43 (39) | 11 (23) | |
Non-Hispanic other race | 13 (12) | 14 (30) | |
Unavailable | 13 (12) | 6 (13) | |
Used hospital’s outpatient pharmacy, n (%) | 60 (55) | 28 (60) | .56 |
No. eligible medications, n (%)b | .28 | ||
1 | 80 (73) | 38 (81) | |
2 | 23 (21) | 5 (11) | |
≥3 | 7 (6) | 4 (8) | |
Class of medication, n (%)b | .79 | ||
Steroid | 37 (34) | 13 (28) | |
Antibiotic or antifungal | 44 (40) | 23 (49) | |
Antiviral | 17 (15) | 6 (13) | |
Other | 12 (11) | 5 (10) | |
APR-DRG of hospitalization, n (%)b | .47 | ||
Asthma | 34 (31) | 11 (23) | |
Respiratory tract infection | 38 (35) | 13 (28) | |
Gastrointestinal problem | 7 (6) | 3 (6) | |
Genitourinary problem | 3 (3) | 4 (9) | |
Skin and soft-tissue infection | 6 (5) | 3 (6) | |
Other | 22 (20) | 13 (28) | |
Weekend discharge, n (%) | 41 (37) | 14 (30) | .37 |
Secondary outcomes, n (%) | |||
AVS missing information | 88 (82) | 36 (77) | .49 |
Discrepant chartb | 3 (3) | 5 (11) | .06 |
Complex dosing | 24 (22) | 15 (32) | .18 |
Total sample size: SES: 106 failures and 45 no failure; discrepant chart: 106 failures and 46 no failure; AVS missing information: 108 failures and 47 no failure. APR-DRG, All Patient Refined Diagnosis Related Group; IQR, interquartile range; LOS, length of stay; —, not applicable.
SES was reported as a z score calculated from small census tract data based on the patient’s home address; it reveals the deviation from the mean of the New York State population.31
Fisher’s exact test was used.